Cross sectional study of p53 immunohistochemical expression of HER2-positive and negative breast cancer patients

Alaa Talib Dawod; Ali Hassan Abood

doi:10.53730/ijhs.v6nS3.6677

Authors

Alaa Talib Dawod
ella.talib1@gmail.com
Faculty of Sciences, University of Kufa, Najaf , Iraq
Ali Hassan Abood Faculty of Sciences, University of Kufa, Najaf , Iraq

Keywords:

breast cancer, HER2-positive negative, p53

Abstract

The current study included forty Iraqi female patients suffered from breast carcinoma were age varied from 34-75 years old, diagnosed through the period from 19 January 2019 to 7 April 2021. In present study used paraffin-embedded of female breast carcinoma sections have been confirmed histological diagnosis such as tumor size, differentiation degree and types of invasive breast cancers after reviewing all slides by specialist pathologists from different centers in AL-Najaf province. Cross sectional study of immunohistochemical expression of biomarker protein P53 (P53) positive and negative females with invasive breast cancers that have been conducted in Middle Euphrates Unit for Cancer Researches / University of Kufa . The highest percentage of P53 over expression was (12.5%) at age (50-59), while the lowest percentage found in age less than 40 years. The results obtained from the present study showed that there was significant difference (p<0.05) between P53 overexpression and patient age and according to histological type appeared of P53ve+ (27.5% in IDC and was (2.5%) in ILC, and P53ve+ which had significant difference (p<0.05) between P53ve+and histopathological type.

Downloads

Download data is not yet available.

References

Takeshita, T., Torigoe, T., Yan, L., Huang, J. L., Yamashita, H., & Takabe, K. (2021). The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer. Cancers, 13(1), 110.‏

Johansson, A. L., Trewin, C. B., Fredriksson, I., Reinertsen, K. V., Russnes, H., & Ursin, G. (2021). In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. Breast Cancer Research, 23(1), 1-10.

Kashyap, D., Garg, V. K., Sandberg, E. N., Goel, N., & Bishayee, A. (2021). Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis. Pharmaceutics, 13(4), 569.‏

Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT et al. (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat109(1): 123–139.

Chen, M. Y., & Gillanders, W. E. (2021). Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound. Breast Cancer: Targets and Therapy, 13, 311.‏

Hayes, D. F. (2019). HER2 and breast cancer—a phenomenal success story. New England Journal of Medicine, 381(13), 1284-1286.

Bai, L., & Zhu, W. G. (2006). p53: structure, function and therapeutic applications. J Cancer Mol, 2(4), 141-153.‏

Borrero, L. J. H., & El-Deiry, W. S. (2021). Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 188556.‏

Azer, S. A. (2021). Clinical Cases in Internal Medicine. Elsevier Health Sciences.‏

Bahreini, F., Rayzan, E., & Rezaei, N. (2021). microRNA‐related single‐ nucleotide polymorphisms and breast cancer. Journal of Cellular Physiology, 236(3), 1593-1605.‏

Gasco, M., Shami, S., & Crook, T. (2002). The p53 pathway in breast cancer. Breast cancer research, 4(2), 1-7.‏

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., ... & Chen, M. (2021). Targeting mutant p53 for cancer therapy: direct and indirect strategies. Journal of Hematology & Oncology, 14(1), 1-19.‏

Munien, C., & Viriri, S. (2021). Classification of Hematoxylin and Eosin-Stained Breast Cancer Histology Microscopy Images Using Transfer Learning with EfficientNets. Computational Intelligence and Neuroscience, 2021(1);1-17.

Kaya, I., Jennische, E., Lange, S., & Malmberg, P. (2021). Multimodal chemical imaging of a single brain tissue section using ToF-SIMS, MALDI-ToF and immuno/histochemical staining. Analyst, 146(4), 1169-1177.

[15] Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble shooting. North American journal of medical sciences, 4(9), 429.

Hsu, S. M., Raine, L., & Fanger, H. (1981). A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. American journal of clinical pathology, 75(5), 734-738.

Alegria-Schaffer, A., Lodge, A., & Vattem, K. (2009). Performing and optimizing Western blots with an emphasis on chemiluminescent detection. Methods in enzymology, 463, 573-599.

Mello, S. S., & Attardi, L. D. (2018). Deciphering p53 signaling in tumor suppression. Current opinion in cell biology, 51, 65-72.‏

Pitolli, C., Wang, Y., Mancini, M., Shi, Y., Melino, G., & Amelio, I. (2019). Do mutations turn p53 into an oncogene?. International journal of molecular sciences, 20(24), 6241.‏

Levesque, M. A., Katsaros, D., Yu, H., Giai, M., Genta, F., Roagna, R. & et al. (1998). Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. International journal of cancer, 79(2), 147-152.‏

Pich, A., Margaria, E., & Chiusa, L. (2000). Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. Journal of clinical oncology, 18(16), 2948-2956..‏

Sierra, A., Castellsague, X., Tortola, S., Escobedo, A., Lloveras, B., Peinado, M. A., & et al. (1996). Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer. Clinical cancer research, 2(11), 1887-1894.

Al-Joudi, F. S., Iskandar, Z. A., & Rusli, J. (2008). The expression of p53 in invasive ductal carcinoma of the breast: a study in the North-East States of Malaysia. Med J Malaysia, 63(2), 96-9.‏

Dash, S. S., Sahu, A., & Toppo, A. (2021). p53 Expression in Breast Carcinoma and Its Association with Tumor Aggressiveness. Journal of Datta Meghe Institute of Medical Sciences University, 16(2), 266.‏

Knoop, A. S., Bentzen, S. M., Nielsen, M. M., Rasmussen, B. B., & Rose, C. (2001). Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. Journal of clinical oncology, 19(14), 3376-3384.‏

Al-Moundhri, M., Al-Bahrani, B., Pervez, I., Ganguly, S. S., Nirmala, V., Al-Madhani, A., & et al.(2004). The outcome of treatment of breast cancer in a developing country—Oman. The Breast, 13(2), 139-145.‏

Whitman, G. J., Albarracin, C. T., & Gonzalez-Angulo, A. M. (2011, January). Triple-negative breast cancer: what the radiologist needs to know. In Seminars in roentgenology (Vol. 46, No. 1, pp. 26-39).‏

Albederi, F. M., Yassin, A., & UK, P. (2012). Immunohistochemical study of breast carcinoma in old age Iraqi women by application of BRCA1 and P53. KUFA MEDICAL JOURNAL, 15(1).‏

Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble shooting. North American journal of medical sciences, 4(9), 429.‏

Middleton, L. P., Palacios, D. M., Bryant, B. R., Krebs, P., Otis, C. N., & Merino, M. J. (2000). Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. The American journal of surgical pathology, 24(12), 1650-1656.‏

Arpino, G., Bardou, V. J., Clark, G. M., & Elledge, R. M. (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast cancer research, 6(3), 1-8.‏

Albederi, F. M., Yassin, A., & UK, P. (2012). Immunohistochemical study of breast carcinoma in old age Iraqi women by application of BRCA1 and P53. KUFA MEDICAL JOURNAL, 15(1).

Mhjoub, S, zahreaei, M, karami, F, Mohagheghi ,M. A. & Zeraeti, H. (1999).Overexpression of p53 protien in malignant breast tumor: an immunohistochemical study. Acta medica Iranica; 37:1-15.

Al-Joudi, F. S., Iskandar, Z. A., & Rusli, J. (2008). The expression of p53 in invasive ductal carcinoma of the breast: a study in the North-East States of Malaysia. Med J Malaysia, 63(2), 96-9.‏

Orucevic, A., Reddy, V. B., Bloom, K. J., Bitterman, P., Magi‐Galluzzi, C., Oleske, D. M., & et al. (2002). Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. The breast journal, 8(6), 349-355.‏

Pich, A., Margaria, E., & Chiusa, L. (2000). Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. Journal of clinical oncology, 18(16), 2948-2956.‏

Lacroix, M., Toillon, R. A., & Leclercq, G. (2006). p53 and breast cancer, an update. Endocrine-related cancer, 13(2), 293-325.‏

Silwal-Pandit, L., Vollan, H. K. M., Chin, S. F., Rueda, O. M., McKinney, S., Osako, T., & et al. (2014). TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clinical Cancer Research, 20(13), 3569-3580.‏

Taneja, S., Evans, A. J., Rakha, E. A., Green, A. R., Ball, G., & Ellis, I. O. (2008). The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. Clinical radiology, 63(11), 1228-1235.‏

Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., & et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology, 27(8), 1160.‏

Castle, J. C., Uduman, M., Pabla, S., Stein, R. B., & Buell, J. S. (2019). Mutation-derived neoantigens for cancer immunotherapy. Frontiers in immunology, 10, 1856.

Andrikopoulou, A., Terpos, E., Chatzinikolaou, S., Apostolidou, K., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & et al. (2021). TP53 mutations determined by targeted NGS in breast cancer: a case-control study. Oncotarget, 12(21), 2206.‏

Ben-David, U., Ha, G., Khadka, P., Jin, X., Wong, B., Franke, L., & Golub, T. R. (2016). The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. Nature communications, 7(1), 1-13.‏

Knoop, A. S., Bentzen, S. M., Nielsen, M. M., Rasmussen, B. B., & Rose, C. (2001). Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. Journal of clinical oncology, 19(14), 3376-3384.‏

Mansour, A., Nirmala, V., Al-Mawaly, K., Ganguly, S., Burney, I., Rizvi, A., & Grant, C. (2003). Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathology & Oncology Research, 9(4), 226-231.‏

Yamashita, H., Nishio, M., Toyama, T., Sugiura, H., Zhang, Z., Kobayashi, S., & Iwase, H. (2003). Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Research, 6(1), 1-7.‏

Bansal, C., Sharma, A., Pujani, M., Pujani, M., Sharma, K. L., Srivastava, A. N., & Singh, U. S. (2017). Correlation of hormone receptor and human epidermal growth factor Receptor-2/neu expression in breast cancer with various clinicopathologic factors. Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology, 38(4), 483.‏

Tsutsui, S., Ohno, S., Murakami, S., Kataoka, A., Kinoshita, J., & Hachitanda, Y. (2003). Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. The American journal of surgery, 185(2), 165-167.‏

Al-Moundhri, M., Al-Bahrani, B., Pervez, I., Ganguly, S. S., Nirmala, V., Al-Madhani, A., & et al. (2004). The outcome of treatment of breast cancer in a developing country—Oman. The Breast, 13(2), 139-145.‏

Lu X, Gu Y, Ding Y, Song W, Mao J, Tan J, & et al. (2008). Correlation of ER, PR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer. Breast J. May-Jun,14(3):308-10.

Chen, Y. Y., Hwang, E. S., Roy, R., DeVries, S., Anderson, J., Wa, C., & et al. (2009). Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. The American journal of surgical pathology, 33(11), 1683.